Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors
Year: 2011
Type: article
Study design: Clinical Trial
Source: Journal of Clinical Oncology
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: anti-EGFR monoclonal antibody, epidermal growth factor receptor, glycoengineered antibody, antibody-dependent cellular cytotoxicity, pharmacokinetics, pharmacodynamics, dose escalation, safety and tolerability, rash, infusion reactions, hypomagnesemia, natural killer cells, colorectal cancer, KRAS mutation, advanced solid tumors, dosing regimen
Open Access status: closed
OpenAlex ID: W2096617104
